All In Biotech

Drug Trial Radar · NCT06492304

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies

A Phase 1/2 Dose Evaluation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed/Refractory Hematologic Malignancies

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Aug 13, 2024

Primary completion

Mar 11, 2026

Study completion Mar 11, 2026

Sponsor

Lead sponsor
CRISPR TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, multicenter, phase 1/2 dose evaluation and cohort expansion study evaluating the safety and efficacy of CTX131 in subjects with Relapsed/Refractory Hematologic Malignancies

Conditions

  • T Cell Lymphoma
  • B Cell Lymphoma
  • Acute Myeloid Leukemia

Interventions

  • CTX131Biological

    CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 Part A (dose escalation) and Part B (dose optimization in selected disease types):Time frame: From CTX131 infusion up to 28 days post-infusion
  2. Objective Response rate (ORR)Time frame: From CTX131 infusion up to 60 months post-infusion
  3. Composite Complete Remission (CRc)Time frame: From CTX131 infusion up to 60 months post-infusion

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site 6

    Phoenix, Arizona

  • Research Site 5

    Stanford, California

  • Research Site 3

    Boston, Massachusetts

  • Research Site 4

    New York, New York

  • Research Site 2

    The Bronx, New York

  • Research Site 1

    Houston, Texas

  • Research Site 7

    East Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.